Emergent BioSolutions acquires manufacturing facility from MdBio

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced Nov. 13 that it has completed the acquisition of a 55,000-square-foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the city of Baltimore for a total purchase price of $8.2 million.

The facility previously operated as a Food and Drug Administration-licensed facility used by an experienced contract manufacturing organization to produce many FDA-approved products.

“Emergent is excited about this new facility in Baltimore because it houses several suites capable of manufacturing multiple products at the same time,” said Fuad El-Hibri, chairman and CEO of Emergent BioSolutions. “Accordingly, this facility will provide the flexibility to conduct large-scale manufacturing of rPA while also producing other products in our pipeline.”

Emergent BioSolutions worked closely with the Maryland Department of Business and Economic Development, MdBio, the city of Baltimore, Baltimore Development Corp. and other related governmental agencies to complete this transaction.

“Maryland is continuing to strengthen its biotechnology prowess by helping to grow industry leaders like Emergent BioSolutions,” Gov. Martin O’Malley said.

Emergent BioSolutions employs more than 600 employees across the globe, with more than 150 employees at its corporate headquarters in Rockville and one of its product development sites in Gaithersburg.

“This acquisition reflects our commitment to both continually creating jobs and investing additional capital in the State of Maryland,” said Daniel J. Abdun-Nabi, president and chief operating officer of Emergent BioSolutions. “We extend our sincere appreciation to the state and local governments for their ongoing support of our efforts to develop our local manufacturing capabilities and look forward to growing Emergent’s presence in the state.”

Emergent BioSolutions is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics. Emergent’s marketed product, BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent BioSolutions’ development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and Chlamydia.

The MdBio Foundation Inc. is a charitable and educational organization whose mission is to provide and support the state of Maryland’s bioscience community through bioscience awareness, education and workforce development programs.